期刊文献+

一种卡马西平共晶的合成及表征 被引量:3

Synthesis and Characterization of a New Pharmaceutical Cocrystal of Carbamazepine
下载PDF
导出
摘要 以卡马西平(CBZ)为药物活性成分,以没食子酸甲酯(MTG)为共晶形成物,在室温下制得一种卡马西平药物共晶CBZ-MTG。通过XRD测得了其晶体结构,并采用FTIR、X射线粉末衍射仪、热重分析仪和差示扫描量热仪对共晶进行了表征。此外,利用HPLC法测试了其溶解性及稳定性。结果表明,共晶CBZ-MTG的熔点为116.4℃,较单一组分CBZ和MTG有了大幅下降;CBZ-MTG在溶解性上也有明显的改观,其在室温下于水和乙醇中的溶解度达到了1.482 6 mmol/L和0.501 2 mol/L,较单一的卡马西平药物分别提高了2.3倍和3.9倍。 A new pharmaceutical cocrystal of carbamazepine(CBZ),CBZ-MTG,was synthesized using methyl gallate(MTG) as a cocrystal coformer at room temperature.Its structure was identified by means of X-ray single crystal diffraction.The CBZ-MTG cocrystal was characterized by Fourier transform infrared spectroscopy(FTIR),X-ray powder diffraction(XRD),thermogravimetric analysis(TGA) and differential scanning calorimetry(DSC).In addition,the solubility and stability were measured by HPLC.The results showed that the melting point of CBZ-MTG cocrystal was 116.4 ℃,which was significantly lower than that of single component.The solubility of CBZ-MTG crystal in water was 1.482 6 mmol/L,and that in ethanol was 0.501 2 mol/L,which was 2.3 times and 3.9 times higher than that of single carbamazepine,respectively.
出处 《精细化工》 EI CAS CSCD 北大核心 2018年第3期437-442,共6页 Fine Chemicals
基金 山东省自然基金(ZR2014HL105) 山东省泰山学者研究基金资助项目(31913)~~
关键词 卡马西平 药物共晶 溶解度 稳定性 医药原料 carbamazepine cocrystal solubility stability drug materials
  • 相关文献

参考文献3

二级参考文献127

  • 1马廷升,朱兰翠.药物生物利用度影响因素的动态分析[J].怀化学院学报,2006,25(2):76-77. 被引量:6
  • 2张伟国,刘昌孝.多晶型药物的生物利用度研究概况[J].天津药学,2007,19(2):59-61. 被引量:13
  • 3[1]Sethia S,Squillante E.Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method[J].J Pharm Sci,2002,91(9):1948-1957.
  • 4[2]Hilfiker R,Berghausen J,Blatter F,et al.Polymorphism-integrated approach from high-throughput screening to crystallization optimization[J].J Therm Anal Calorim,2003,73(2):429-440.
  • 5[3]Hickey MB,Peterson ML,Scoppettuolo LA,et al.Performance comparison of a co-crystal of carbamazepine with marketed product[J].Eur J Pharm Biopharm,2007,67(1):112-119.
  • 6[4]Carino SR,Sperry DC,Hawley M.Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model[J].J Pharm Sci,2006,95(1):116-125.
  • 7[5]Kobayashi Y,Ito S,Itai S,et al.Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate[J].Int J Pharm,2000,193(2):137-146.
  • 8[6]Dong WY,Maincent P,Bodmeier R.In vitro and in vivo evaluation of carbamazepine-loaded enteric microparticles[J].Int J Pharm,2007,331(1):84-92.
  • 9[7]Filipovi c-Grcic J,Perissutti B,Moneghini M,et al.Spray-dried carbamazepine-loaded chitosan and HPMC microspheres:preparation and characterisation[J].J Pharm Pharmacol,2003,55(7):921-931.
  • 10[8]Passerini N,Perissutti B,Moneghini M,et al.Characterization of carbamazepine-Gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds[J].J Pharm Sci,2002,91(3):699-707.

共引文献85

同被引文献14

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部